Diabetes, hyperlipidemia, and coronary artery disease

American Journal of Cardiology

Volumn 83, Issue 9 B, 1999, Pages

  Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; SIMVASTATIN;

CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033551403     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00213-1     Document Type: Conference Paper

References (22)

1. Kannel W.B., McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease the Framingham Study . Diabetes Care. 2:1979;120-126.
2. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 39:1998;229-234.
3. Wagenknecht L.E., D'Agostino R.B. Jr, Haffner S.M., Savage P.J., Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness the Insulin Resistance Atherosclerosis Study . Diabetes Care. 21:1998;1812-1818.
4. Miettenen H., Lehto S., Salomaa V., Mahonen M., Niemela M., Haffner S.M., Pyörälä K., Tuomilehto J. Impact of diabetes on mortality after first myocardial infarction. Diabetes Care. 21:1998;69-75.
5. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care. 21:1998;160-178.
6. Wilson P.W., Kannel W.B., Anderson K.M. Lipids, glucose tolerance and vascular disease the Framingham Study . Monogr Atheroscler. 13:1985;1-11.
7. Position paper Management of dyslipidemia in adults with diabetes . Diabetes Care. 21:1998;179-182.
8. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
9. Laakso M., Lehto S., Penttila I., Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 88:1993;1421-1430.
10. Després J.-P., Lamarche B., Mauriége P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957.
11. Lamarche B., Tchernof A., Mauriege P., Cantin B., Dagenais G.R., Lupien P.J., Després J.-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 279:1998;1955-1961.
12. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
14. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Jr. Design and rationale for the Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS). Am J Cardiol. 80:1997;287-293.
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
16. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
17. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., Nikkilä E.A. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
18. Koskinin P., Manttari M., Manninen V., Huttunen J.K., Heinonen O.P., Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 15:1992;820-825.
19. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., Richmond W., Mather H., Sharp P., Feher M.D. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care. 21:1998;641-648.
20. Adkins J.C., Faulds D. Micronised fenofibrate a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia . Drugs. 54:1997;615-633.
21. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia. 39:1996;1655-1661.
22. Caslake M.J., Feher M.D., Foxton J., Lant A.F., Packard C.J. Atherogenic lipoprotein phenotype in non-insulin-dependent diabetes reversal with micronized fenofibrate . Diabetic Med. (Suppl 7):1997;S12.